Market capitalization | CHF198.91b |
Enterprise Value | CHF223.13b |
PER (TTM) P/E ratio | 17.32 |
EV/FCF (TTM) EV/FCF | 18.99 |
EV/Sales (TTM) EV/Sales | 3.80 |
P/S ratio (TTM) P/S ratio | 3.39 |
P/B ratio (TTM) P/B ratio | 6.79 |
Dividend yield | 3.85% |
Last dividend (FY23) | CHF9.60 |
Activate alerts on the share price, dividend yield, valuation (e.g. P/E ratio or EV/sales) or strategy scores and sit back and relax.
23 Analysts have issued a Roche forecast:
23 Analysts have issued a Roche forecast:
Dec '23 |
+/-
%
|
||
Turnover | 58,716 58,716 |
7%
7%
|
|
Gross income | 42,898 42,898 |
3%
3%
|
|
EBITDA | 19,823 19,823 |
10%
10%
|
EBIT (operating result) EBIT | 16,349 16,349 |
10%
10%
|
Net profit | 11,498 11,498 |
7%
7%
|
Figures in millions CHF.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
Head office | Switzerland |
CEO | Thomas Schinecker |
Employees | 103,605 |
Founded | 1896 |
Website | www.roche.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.